Last reviewed · How we verify
NCT06211543
Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
trial in CMV in 80 participants. Status unknown.
30 September 2025
Quick facts
| Lead sponsor | Grupo Espanol de trasplantes hematopoyeticos y terapia celular |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 30 March 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 March 2026 |
Conditions studied
- CMV — all drugs for CMV →
Sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Who can join
18 and older, any sex, with CMV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational cohort study. Two cohort will be enrolled: LMV cohort: All patients included in in this study will receive LMV according to standard of care. Historical cohort: an historical cohort will be included to compare the results of both groups (LMV vs historical cohort).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06211543
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CMV
Currently open trials in the same condition.
- NCT06812598 — Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogenei · NA · recruiting
- NCT06011486 — Expansion of Virus-Specific Lymphocytes for Cell Therapy · Phase 1 · recruiting
- NCT06001320 — De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients · Phase 3 · active not recruiting
- NCT04056533 — Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy · Phase 2 · recruiting
- NCT01011712 — The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunoco · recruiting
Other Grupo Espanol de trasplantes hematopoyeticos y terapia celular trials
Trials by the same sponsor.
- NCT05390671 — CAR-T Cell Therapy in Patients With Hematological Malignancies · completed
- NCT03415867 — Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06211543 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grupo Espanol de trasplantes hematopoyeticos y terapia celular
- Last refreshed: 18 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06211543.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing